Trials / Terminated
TerminatedNCT00286169
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amrubicin Hydrochloride |
Timeline
- Start date
- 2006-04-01
- First posted
- 2006-02-03
- Last updated
- 2022-04-12
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00286169. Inclusion in this directory is not an endorsement.